Lange W, Snyder D S, Castro R, Rossi J J, Blume K G
Stanford University School of Medicine, CA.
Blood. 1989 May 1;73(6):1735-41.
The Philadelphia chromosome of chronic myelogenous leukemia (CML) patients is caused by a translocation of the c-abl gene from chromosome 9 to the breakpoint cluster region (bcr) on chromosome 22. A new bcr-abl mRNA is expressed in these cases. We have developed a modified polymerase chain reaction (PCR) for the detection of this mRNA. The method is extremely sensitive, reliable, and relatively fast. The analysis of peripheral blood or bone marrow cells from CML patients treated with chemotherapy shows that the two possible mRNAs are expressed in various combinations. Our results show that even after myeloablative therapy for bone marrow transplantation bcr-abl mRNAs are still expressed. Further studies, however, are necessary to determine the clinical relevance of a small number of persisting cells expressing the bcr-abl mRNA.
慢性粒细胞白血病（CML）患者的费城染色体是由c-abl基因从9号染色体易位至22号染色体的断裂簇区域（bcr）所致。在这些病例中会表达一种新的bcr-abl mRNA。我们已开发出一种改良的聚合酶链反应（PCR）用于检测这种mRNA。该方法极其灵敏、可靠且相对快速。对接受化疗的CML患者的外周血或骨髓细胞分析表明，两种可能的mRNA以各种组合形式表达。我们的结果显示，即使在进行骨髓移植的清髓治疗后，bcr-abl mRNA仍会表达。然而，仍需进一步研究来确定少数表达bcr-abl mRNA的持续存在细胞的临床相关性。
